Menu
Prakriti Gaba, MD
Pronouns
She/Her/Hers
Job Title
Cardiology Fellow
Academic Rank
Instructor
Department
Medicine
Authors
Prakriti Gaba, M.D.,1 Deepak L. Bhatt, M.D., M.P.H.,1 Ph. Gabriel Steg, M.D.,2 Michael Miller, M.D.,3 Eliot A. Brinton, M.D.,4 Terry A. Jacobson, M.D.,5 Steven B. Ketchum, Ph.D.,6 Rebecca A. Juliano, Ph.D.,6 Lixia Jiao, Ph.D.,6 Ralph T. Doyle, Jr., B.A.,6 Craig Granowitz, M.D., Ph.D.,6 Jean-Claude Tardif, M.D.,7 Robert P. Giugliano, M.D., S.M.,1 Fabrice MAC Martens, M.D., Ph.D.,8 C. Michael Gibson, M.D.,8 Christie M. Ballantyne, M.D.,9 on Behalf of the REDUCE-IT Investigators
Principal Investigator
Deepak Bhatt
Research Category: Cardiovascular, Diabetes, and Metabolic Disorders
Tags
Background: REDUCE-IT was a double-blind trial that randomized 8179 statin-treated patients with controlled low-density lipoprotein cholesterol (LDL-C) and moderately elevated triglycerides to icosapent ethyl (IPE) or placebo. There was a significant reduction in the primary endpoint, including death from cardiovascular (CV) causes. The specific impact of IPE among patients with prior myocardial infarction (MI) was unknown.
Objectives: Our goal was to examine the benefit of IPE on ischemic events among patients with prior MI in REDUCE-IT.
Methods: We performed post hoc analyses of patients with prior MI. The primary endpoint was CV death, MI, stroke, coronary revascularization, or hospitalization for unstable angina. The key secondary endpoint was CV death, MI, or stroke.
Results: A total of 3693 patients had a history of prior MI. The primary endpoint was reduced from 26.1% to 20.2% with IPE versus placebo, HR 0.74 (95% CI 0.65-0.85), P=0.00001. The key secondary endpoint was reduced from 18.0% to 13.3%, HR 0.71 (95% CI 0.61-0.84), P=0.00006. There was also a significant 35% relative risk reduction in total ischemic events (P=0.0000001), a 34% reduction in MI (P=0.00009), a 30% reduction in CV death (P=0.01), and a 20% lower rate of all-cause mortality (P=0.05), though there was a slight increase in atrial fibrillation. Sudden cardiac death and cardiac arrest were also significantly reduced by 40% and 56%, respectively.
Conclusions: Patients with a history of prior MI in REDUCE-IT treated with IPE demonstrated large and substantial relative and absolute risk reductions in ischemic events, including CV death.
Background: REDUCE-IT was a double-blind trial that randomized 8179 statin-treated patients with controlled low-density lipoprotein cholesterol (LDL-C) and moderately elevated triglycerides to icosapent ethyl (IPE) or placebo. There was a significant reduction in the primary endpoint, including death from cardiovascular (CV) causes. The specific impact of IPE among patients with prior myocardial infarction (MI) was unknown.
Objectives: Our goal was to examine the benefit of IPE on ischemic events among patients with prior MI in REDUCE-IT.
Methods: We performed post hoc analyses of patients with prior MI. The primary endpoint was CV death, MI, stroke, coronary revascularization, or hospitalization for unstable angina. The key secondary endpoint was CV death, MI, or stroke.
Results: A total of 3693 patients had a history of prior MI. The primary endpoint was reduced from 26.1% to 20.2% with IPE versus placebo, HR 0.74 (95% CI 0.65-0.85), P=0.00001. The key secondary endpoint was reduced from 18.0% to 13.3%, HR 0.71 (95% CI 0.61-0.84), P=0.00006. There was also a significant 35% relative risk reduction in total ischemic events (P=0.0000001), a 34% reduction in MI (P=0.00009), a 30% reduction in CV death (P=0.01), and a 20% lower rate of all-cause mortality (P=0.05), though there was a slight increase in atrial fibrillation. Sudden cardiac death and cardiac arrest were also significantly reduced by 40% and 56%, respectively.
Conclusions: Patients with a history of prior MI in REDUCE-IT treated with IPE demonstrated large and significant relative and absolute risk reductions in ischemic events, including CV death.
